Patterns of Proton Beam Therapy Use in Clinical Practice Between 2007 and 2019 in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Proton beam therapy (PBT) is a state-of-the-art technology employed in radiotherapy (RT) for cancer patients. This study characterized how PBT has been used in clinical practice in Korea. Materials and Methods Patients who received any type of RT between 2007 and 2019 were identified from the radiation oncology registry of the two PBT facilities operating in Korea (National Cancer Center and Samsung Medical Center). The chi-square test was used to identify patient- and treatment-related characteristics associated with the receipt of PBT. Results A total of 54,035 patients had been treated with some form of RT in the two institutions, of whom 5,398 received PBT (10.0%). The number of patients who receive PBT has gradually increased since PBT first started, from 162 patients in 2007 to 1,304 patients in 2019. Among all types of cancer, PBT use in liver cancer has been steadily increasing from 20% in 2008-2009 to 32% in 2018-2019. In contrast, that in prostate cancer has been continuously decreasing from 20% in 2008-2009 to < 10% in 2018-2019. Male sex, very young or old age, stage I-II disease, residency in non-capital areas, a definitive setting, a curative treatment aim, enrollment in a clinical trial, re-irradiation and insurance coverage were significantly associated with the receipt of PBT (all p < 0.05). Conclusion Since PBT started in Korea, the number of patients receiving PBT has increased to more than 1,000 per year and treatment indications have expanded. Liver cancer is the most common primary tumor among all PBT cases in Korea.
Abstract
Purpose Proton beam therapy (PBT) is a state-of-the-art technology employed in radiotherapy (RT) for cancer patients. This study characterized how PBT has been used in clinical practice in Korea. Materials and Methods Patients who received any type of RT between 2007 and 2019 were identified from the radiation oncology registry of the two PBT facilities operating in Korea (National Cancer Center and Samsung Medical Center). The chi-square test was used to identify patient- and treatment-related characteristics associated with the receipt of PBT. Results A total of 54,035 patients had been treated with some form of RT in the two institutions, of whom 5,398 received PBT (10.0%). The number of patients who receive PBT has gradually increased since PBT first started, from 162 patients in 2007 to 1,304 patients in 2019. Among all types of cancer, PBT use in liver cancer has been steadily increasing from 20% in 2008-2009 to 32% in 2018-2019. In contrast, that in prostate cancer has been continuously decreasing from 20% in 2008-2009 to < 10% in 2018-2019. Male sex, very young or old age, stage I-II disease, residency in non-capital areas, a definitive setting, a curative treatment aim, enrollment in a clinical trial, re-irradiation and insurance coverage were significantly associated with the receipt of PBT (all p < 0.05). Conclusion Since PBT started in Korea, the number of patients receiving PBT has increased to more than 1,000 per year and treatment indications have expanded. Liver cancer is the most common primary tumor among all PBT cases in Korea.
참고문헌 (30)
- Delaney G, "The role of radiotherapy in cancer treatment : estimating optimal utilization from a review of evidence-based clinical guidelines", Cancer, 104, pp.1129~1137 (2005)
- Bagshaw MA, "Prostate cancer. Radiation therapy for localized disease", Cancer, 71, pp.939~952 (1993)
- Brada M, "Proton therapy in clinical practice : current clinical evidence", J Clin Oncol, 25, pp.965~970 (2007)
- "Particle Therapy Co-operative Group" (2020)[URL]
- Noel G, "Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams", Acta Oncol, 44, pp.700~708 (2005)
- Dendale R, "Proton beam radiotherapy for uveal melanoma : results of Curie Institut-Orsay proton therapy center(ICPO)", Int J Radiat Oncol Biol Phys, 65, pp.780~787 (2006)
- Gragoudas ES, "Long-term risk of local failure after proton therapy for choroidal", ciliary body melanoma, 2002, pp.100, 43~48
- Munzenrider JE, "Proton therapy for tumors of the skull base", Strahlenther Onkol, 175(Suppl 2), pp.57~63 (1999)
- Baumann BC, "Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer", JAMA Oncol, 6, pp.237~246 (2020)
- Jereczek-Fossa BA, "Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer", Int J Radiat Oncol Biol Phys, 82, pp.889~897 (2012)
- Lee SU, "Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : ablative dose PBT for NSCLC", Strahlenther Onkol, 192, pp.649~657 (2016)
- Lee SU, "Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", Strahlenther Onkol, 190, pp.806~814 (2014)
- 김태현, "Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma", Cancer Research and Treatment, 47(1), pp.34~45 (2015), 대한암학회[DOI]
- Chuong MD, "Improving outcomes for esophageal cancer using proton beam therapy", Int J Radiat Oncol Biol Phys, 95, pp.488~497 (2016)
- Bishop AJ, "Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma : multi-institutional analysis of outcomes, cyst dynamics, and toxicity", Int J Radiat Oncol Biol Phys, 90, pp.354~361 (2014)
- McAvoy SA, "Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer", Radiother Oncol, 109, pp.38~44 (2013)
- Parikh-Patel A, "A population-based assessment of proton beam therapy utilization in California", Am J Manag Care, 26, pp.e28~35 (2020)
- Kim E, "Clinical utilization of radiation therapy in Korea, 2016", J Radiat Res, 61, pp.249~256 (2020)
- Kamada T, "Carbon ion radiotherapy in Japan : an assessment of 20 years of clinical experience", Lancet Oncol, 16, pp.e93~100 (2015)
- 허승재, "Current status and comparison of national health insurance systems for advanced radiation technologies in Korea and Japan", Radiation oncology journal, 38(3), pp.170~175 (2020), 대한방사선종양학회
- Hahn C, "Choosing wisely : the American Society for Radiation Oncology’s top 5 list", Pract Radiat Oncol, 4, pp.349~355 (2014)
- Bush DA, "The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma : a phase 2 prospective trial", Cancer, 117, pp.3053~3059 (2011)
- Hong TS, "Multi-institutional phase II study of highdose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma", J Clin Oncol, 34, pp.460~468 (2016)
- Kim TH, "Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma", Front Oncol, 10, pp.542~ (2020)
- Kawashima M, "Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma", J Clin Oncol, 23, pp.1839~1846 (2005)
- Kim TH, "Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial", J Hepatol, 74, pp.603~612 (2021)
- Ran Xu Zhu, "Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region", Gut and Liver, 10(3), pp.332~339 (2016), 거트앤리버 소화기연관학회협의회
- 허승재, "Recent trends in intensity-modulated radiation therapy use in Korea", Radiation oncology journal, 37(4), pp.249~253 (2019), 대한방사선종양학회
- Ryckman JM, "National practice patterns of proton versus photon therapy in the treatment of adult patients with primary brain tumors in the United States", Acta Oncol, 58, pp.66~73 (2019)
- Shen CJ, "Socioeconomic factors affect the selection of proton radiation therapy for children", Cancer, 123, pp.4048~4056 (2017)